Tweet The drug class being used increasingly are the anti-CD20 depleting drugs. There are more and more of them. So which do you choose? They all target CD2O and they are all based on human IgG1, but are they the same? The battle for the sales team is how they position thier drugs to get…
Guest Voice: Who knew MS and bipolar disorder were connected?
I am a 63-year-old psychologist, clinician, professor, and poster child for multiple sclerosis (MS). After more than 30 years with the disease, I’m still mobile, sometimes with a cane. My speech isn’t impaired, though my volume is, and my memory is taking a nosedive. I have no working taste buds, no proprioception, and I’m slow…
Nourishing November with Fall Traditions
By: Dr. Eva Jackson As the crisp air settles in and leaves turn golden, the fall season welcomes a tapestry of festivals, holidays, and cherished family gatherings. The sights of autumn begin with vibrant wreaths and pumpkins adorning front porches, … Continue reading → Source: blog.mymsaa.org
New Tysabri biosimilar Tyruko now on market for relapsing MS
Tyruko (natalizumab-sztn) is now commercially available in the U.S. as the first and only approved biosimilar to Tysabri for adults with relapsing forms of multiple sclerosis (MS). The therapy received approval from the U.S. Food and Drug Administration (FDA) in 2023 for all indications covered by the brand-name medicine, including clinically isolated syndrome, relapsing-remitting MS (RRMS),…
New trial explores whether EBV vaccine can slow early MS activity
A clinical trial is now recruiting participants to test whether an experimental vaccine for the Epstein-Barr virus (EBV) is safe and may help reduce disease activity in people with multiple sclerosis (MS). The Phase 2 study (NCT06735248) aims to enroll 180 adults, ages 18 to 55, with relapsing forms of MS who were diagnosed within…
What is the root cause of secondary autoimmunity after alemtuzumab
Tweet Sandgren S, Novakova L, Axelsson M, Rosenstein I, Lycke JN, Malmeström C. Lymphocyte Dynamics and the Emergence of Secondary Autoimmunity Following Immune Reconstitution Therapies in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2025;12(6):e200497. Background and objectives: Understanding the immunologic changes induced by immune reconstitution therapies (IRTs) is key to optimizing multiple sclerosis (MS) treatment. We evaluate lymphocyte…
PML testing..the tale of two companies.
Tweet This study reports that the JC virus tests for Tysbari manufacturer and the Tyruko manufacturer and implied that they are more or less the same based on their head to head study. However, there are other studies where there are differences notably at the lower end and the Tyruko JC virus test finds more…
Drowning In Life
Happy Midweek, y’all! I hope you are having a good week. Once we are at the halfway point of the week, the weekend is getting closer, and the last part of the week should be easier to get through. During the first half of your week, what was the best part for you? I will try to…
Holiday Wellness Bingo Card
By Stacie Prada Each year, the holiday season is a time of increased tasks, deadlines, and obligations. It can be stressful doing everything I need and want to do. Add managing my health issues with multiple sclerosis, and it can … Continue reading → Source: blog.mymsaa.org
MOGAD has unique immune signature distinct from MS: Study
Multiple sclerosis (MS) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) share similar symptoms but are two biologically distinct conditions, with different immune signatures, a study found. These findings help explain why treatments approved for MS generally show limited effectiveness for MOGAD, researchers said. “These findings support MOGAD as its own disease entity, distinct from other…